The Tohoku journal of experimental medicine
-
Tohoku J. Exp. Med. · Jan 2025
Long Noncoding RNA GAS5 Contributes to Mycoplasma Pneumoniae Pneumonia by Regulating NF-κB via MiR-29c/HMGB1 Axis.
Mycoplasma pneumoniae pneumonia (MPP) poses a major threat to pediatric health. Our previous study suggested that GAS5 level was elevated in the peripheral blood of MPP children. However, the mechanism by which GAS5 regulates lung inflammation Mycoplasma pneumoniae (MP) infection-induced remains unknown. ⋯ Ectopic expression of GAS5 counteracted the effect of miR-29c mimic, and miR-29c inhibitor counteracted the effect of HMGB1 knockdown. Furthermore, silencing of GAS5 significantly alleviated MPP-induced inflammation and pathological lung injury in the MPP mouse model. GAS5/miR-29c/HMGB1 is highly involved in inflammation and lung histopathological injury in MPP disease progression by regulating the NF-κB signaling pathway.
-
Tohoku J. Exp. Med. · Jan 2025
Etiological Characteristics and Risk Factors of Chronic Obstructive Pulmonary Disease Combined with Infection.
The distribution characteristics of pathogenic bacteria and the related health risk of pulmonary infection in patients with chronic obstructive pulmonary disease (COPD) were retrospectively analyzed to develop targeted measures to enhance patient prognosis. A retrospective analysis was conducted on the clinical data of 108 patients with COPD complicated with pulmonary infection and 108 patients without pulmonary infection. Analyze the distribution of pathogens in the lung infection group. ⋯ Forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) were significantly lower than in the group without pulmonary infection (P < 0.05). Multivariate Logistic regression analysis showed that unrelated health risks for pulmonary infection in COPD patients were age ≥ 60 years, length of hospitalization ≥ 15 days, combination of diabetes mellitus, and use of ≥ 2 types of antibacterial drugs. Age ≥ 60 years old, hospital stay ≥ 15 days, diabetes patients, and antibacterial drugs ≥ 2 are the risk factors of COPD patients with pulmonary infection.